July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Identification of Novel Biomarkers in Geographic Atrophy using Wide Spectrum Multiplexing
Author Affiliations & Notes
  • Kameran Lashkari
    Schepens Eye Research Institute, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Gianna C Teague
    Schepens Eye Research Institute, Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Ursula Beattie
    Harvard Stem Cell Center, Harvard University, Boston, Massachusetts, United States
  • Megan McLaughlin
    Virtual Proof of Concept DPU, GlaxoSmithKline, King of Prussia, Pennsylvania, United States
  • Francisco J. Lopez
    Ophthalmology, Allergan plc, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Kameran Lashkari, None; Gianna Teague, None; Ursula Beattie, None; Megan McLaughlin, GlaxoSmithKline (E); Francisco Lopez, Allergan Inc. (E)
  • Footnotes
    Support  Funded by GlaxoSmithKline
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2417. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kameran Lashkari, Gianna C Teague, Ursula Beattie, Megan McLaughlin, Francisco J. Lopez; Identification of Novel Biomarkers in Geographic Atrophy using Wide Spectrum Multiplexing. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2417.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Local inflammation is associated with development and progression of geographic atrophy (GA) associated with age-related macular degeneration (AMD). Despite recent studies targeting the alternative complement pathway for treatment of GA, the biomarker profile of GA has not been fully studied. In this study, we used a wide spectrum approach (multiplex immunoassays) to identify factors that were associated with GA, and distinct from intermediate dry AMD.

Methods : Levels of 320 factors were analyzed by multiplex immunoassays in a cohort of 91 subjects (63F:31M; mean age 77 years). Subjects were divided into 3 groups based on clinical diagnostic criteria: Controls (AREDS 0), intermediate dry AMD (AREDS stage III) and Geographic Atrophy (AREDS 4/5 from a GSK-sponsored study, NCT01342926). Results were evaluated for quality control and then analyzed by Kruskal-Wallis, Principal Component Analysis, partial least squares, MANOVA, and univariate ANCOVAs. Of 320 factors, 40 were identified as highly significant. These factors were then re-evaluated using individual ELISAs in a second cohort of 86 subjects (56F:30M, mean age 77 years). Results were analyzed using similar methodology.

Results : In the first Cohort, 40 factors including amyloid-β (Aβ)(1-40) were significantly elevated in GA (P=0.013). There was a statistically significant linear trend among the three diagnostic groups (P<0.05). The levels of Aβ(1-42) were not significantly elevated. In the second Cohort, ELISA analysis of the 40 factors identified 12 factors including Aβ(1-40) that were elevated (P=0.01); Aβ(1-42) levels were not elevated. Analysis of protein clustering versus enriched pathways showed that many of factors identified were functionally connected to the Aβ pathways (Fisher’s exact test, P<0.01).

Conclusions : Using wide spectrum approaches for biomarker analysis, we initially identified 40 and subsequently confirmed 12 factors that were significantly associated with GA in 2 clinical cohorts. Among these factors, Aβ(1-40) was significantly elevated while Aβ(1-42) was not elevated. The remaining factors that were elevated in both cohorts with GA interact with Aβ. Targeting these factors may have therapeutic applications in treatment of GA.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×